GlaxoSmithKline Files for European Approval of Diabetes Drug Albiglutide
About albiglutide
Albiglutide, a GLP-1 receptor agonist, is an investigational biological product for the treatment of type 2 diabetes designed for once-weekly subcutaneous dosing. GLP-1 is a peptide that is normally secreted from the gastrointestinal tract during a meal which in turn helps release insulin to control blood sugar elevations after eating. In people with type 2 diabetes, GLP-1 secretion in response to a meal is reduced or absent. GLP-1 is rapidly degraded while albiglutide has been developed to have a longer duration of action by being comprised of two copies of modified human GLP-1 fused in series to human albumin.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
GlaxoSmithKline Enquiries:
UK Media enquiries:
David Mawdsley
+44 (0) 20 8047 5502
(London)
Sarah Spencer
+44 (0) 20 8047 5502
(London)
David Daley
+44 (0) 20 8047 5502
(London)
Catherine Hartley
+44 (0) 20 8047 5502
(London)
Alex Harrison
+44 (0) 20 8047 5502
(London)
US Media enquiries:
Stephen Rea
+1 215 751 4394
(Philadelphia)
Kevin Colgan
+1 919 483 2933
(North Carolina)
Melinda Stubbee
+1 919 483 2510
(North Carolina)
Mary Anne Rhyne
+1 919 483 0492
(North Carolina)
Sarah Alspach
+1 202 715 1048
(Washington, DC)
Jennifer Armstrong
+1 215 751 5664
(Philadelphia)
Analyst/Investor enquiries:
Sally Ferguson
+44 (0) 20 8047 5543
(London)
Lucy Budd
+44 (0) 20 8047 2248
(London)
Tom Curry
+ 1 215 751 5419
(Philadelphia)
Gary Davies
+ 44 (0) 20 8047 5503
(London)
James Dodwell
+ 44 (0) 20 8047 2406
(London)
Jeff McLaughlin
+ 1 215 751 7002
(Philadelphia)
Ziba Shamsi
+ 44 (0) 20 8047 3289
(London)